Publicacións (42) Publicacións nas que participase algún/ha investigador/a

2024

  1. A new framework for the diagnosis, staging and management of obesity in adults

    Nature Medicine

  2. Cardiometabolic risk stratification using a novel obesity phenotyping system based on body adiposity and waist circumference

    European Journal of Internal Medicine, Vol. 124, pp. 54-60

  3. Clinical Perspectives, Eligibility, and Success Criteria for Bariatric/Metabolic Surgery

    Advances in experimental medicine and biology, Vol. 1460, pp. 677-695

  4. Comment on: “Pregnancy Outcomes After Bariatric Surgery: Importance of Maternal Ferritin on Birth Weight”

    Obesity Surgery

  5. Consenso del grupo de trabajo de los trastornos de la conducta alimentaria de SENPE (GTTCA-SENPE). Evaluación y tratamiento médico-nutricional en la anorexia nerviosa. Actualización 2023

    Nutricion hospitalaria, Vol. 41, Núm. 1, pp. 1-60

  6. Decreased expression of the NLRP6 inflammasome is associated with increased intestinal permeability and inflammation in obesity with type 2 diabetes

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  7. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  8. Differential mitochondrial adaptation and FNDC5 production in brown and white adipose tissue in response to cold and obesity

    Obesity

  9. Does the Prevalence of Obesity in the Different Regions of Spain Influence the Attitudes, Perception, and Barriers to Its Treatment?

    Obesity Facts, Vol. 17, Núm. 3, pp. 264-273

  10. Drug approach to treatment for obesity in adults: perspectives and considerations

    Revista Espanola de Enfermedades Digestivas

  11. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    Obesity Facts, Vol. 17, Núm. 4, pp. 374-444

  12. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

    Journal of Hepatology, Vol. 81, Núm. 3, pp. 492-542

  13. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary

    Diabetologia

  14. Enhancing the management of chronic diseases in clinical practice: The CARABELA methodology

    Journal of Healthcare Quality Research, Vol. 39, Núm. 5, pp. 336-339

  15. Epicardial and liver fat implications in albuminuria: a retrospective study

    Cardiovascular Diabetology, Vol. 23, Núm. 1

  16. FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease

    Clinical Nutrition, Vol. 43, Núm. 9, pp. 2221-2233

  17. Glucometrics knowledge and its relationship to glycemic control in people living with type 1 diabetes: The GluKometrics study: Glucometrics knowledge and glycemic control in type 1 diabetes.

    Diabetes and Metabolism

  18. Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?

    European Journal of Internal Medicine, Vol. 119, pp. 13-30

  19. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

  20. Impact of primary aldosteronism on kidney function: Results from the SPAIN-ALDO registry

    Journal of Hypertension, Vol. 42, Núm. 10, pp. 1805-1812